Surmodics, Inc. SRDX demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than the market estimate and sales beat the same by 8.3%. The strong ...

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care ...

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered ...

Surmodics is a medical device maker that makes coatings for medical devices and manufactures chemicals for diagnostic immunoassay tests The company will make a drug-coated balloon that will be sold by ...

Surmodics looks to pave a new path forward after the FDA sent a device submission back for revision yet again. The device in question is its SurVeil drug-coated balloon, which is threaded into a blood ...

Shares of SurModics (SRDX) have been on an upswing since reporting a solid fiscal third quarter in early August, and recently hit its 52-week high of $22.21 on October 5. With a year-to-date return of ...

Abbott has secured the global rights to Surmodics’ drug-coated balloon (DCB). The company is paying $25 million upfront and committing to up to $67 million in development milestones to add the device ...

Surmodics, Inc. SRDX is a leading provider of medical device and in vitro diagnostic technologies to the health care industry that could be an interesting play for investors. That is because, not only ...

SurModics (SRDX) is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Surmodics, Inc. SRDX demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than the market estimate, and sales beat the same by 8.3%. The strong ...